The following post is one of a series of posts appearing Monday through Friday on The Cancer Blog. This feature -- Today, I am grateful -- allows me to share with readers my appreciation for all the treasures in my life, both big and small. In my post-cancer world, I find It healing for my soul to be mindful of the good in my life. It is my pleasure to share my gratitude with you.

The night before my lumpectomy, way back in December 2005, I was consumed with fear, worry, and panic. Since I'd found it, the lump in my left breast had been sitting untouched for nearly two weeks. I imagined the mass spreading with each day and believed I could detect its growth each time I felt for it. A doctor told me if it was growing like I thought it was, my tiny pea-sized tumor would be the size of an apple within days.

My fears were unfounded and irrational. I know that now. But during the moments of uncertainty that filled my days between diagnosis and prognosis, I had no direction. I had only my wandering mind for company. The waiting really is the hardest part. Once faced with the specifics of our diseases, we can take action.

Cancer is named from the place it originates. This makes a difference on what type of treatments will be effective. Being diagnosed with cancer of the unknown primary (CUP) means that cancer has been found in the body but the place of origin is unknown.

If later, the place of origin is found then the type of cancer diagnosis changes from an unknown primary to the specific organ or body area that the disease first began.

Some cases of cancer of the unknown primary are unfortunately never found. Physicians will then decide on the best course of treatment based on two factors: The way the cells look under the microscope and which organs are currently involved.

Statistics and Prognosis:

The exact number of cases of this disease is not known. It may be about 2% to 5% of all cancers in the United States. It is found more often among men than among women. The average age of people with this cancer is about 60 years.

This is a very dangerous cancer. Only half of patients will live 9 to 12 months after their cancer is found. There are several reasons why this cancer is so serious. First, most of these are fast-spreading cancers. Second, because the exact type is not known, it is harder for doctors to know what treatment is best. Also, the cancer is often widespread, making it harder to cure.

In recent years, microscopic and other diagnostic techniques have improved dramatically. For this reason, doctors can now determine the primary site in about four out of five cases.

Merv Griffin, creator and producer of TV game shows Jeopardy! and Wheel of Fortune, announced in July that he'd been diagnosed once again with prostate cancer. Hospitalized after the cancer recurrence was detected during a routine examination, Griffin was reportedly doing fine. New reports indicate Griffin's prognosis is not so fine, although his reps won't confirm of deny this.

It is clear Griffin is still in the hospital. Sources close to him say he is putting all his strength into fighting this battle with cancer.

In lieu of sending him flowers, Griffin asks that well-wishers donate to the Young Musicians Foundation -- an organization he chairs. Also, messages can be sent here.

Discussions about cancer often include mention of age. We talk about how old someone is at diagnosis, how old a person is at each year of survival, the age of an individual at the time cancer claims his or her life. Age reveals a lot. It dumps us into statistical categories. Most patients diagnosed with gallbladder cancer, for example, are older than 65. Age sometimes predicts prognosis. Young women diagnosed with breast cancer tend to have more aggressive forms of the disease. This can compromise chances for survival. Age also solicits judgments. "You are too young," some people told me after learning I'd been diagnosed with breast cancer.

I think about my age all the time. I think about how I was 34 when I found my lump, how I happily arrived at age 35, how I made it to 36, and how today, I am 37. Come November, I will have survived my disease for three years. Three years will remain before I make it out of my 30s and land on 40 -- the age when women should begin receiving regular annual mammograms.

I didn't ask for much this year for my birthday. A candle, a bathing suit, dinner out with my husband, and time with family are all I really want -- because the best gift has already arrived. I turned 37.

I found David's website while researching about Glioblastoma Multiforme (GBM), the most aggressive type of brain tumor. I found his website to be very inspiring. My uncle died of GBM twenty years ago this coming holiday season. David is an 11 year survivor this year! You can visit David's website at www.davidmbailey.com.

How did you find out you had cancer?

I started getting these really bad headaches. One morning, I fell over and felt nauseous. My wife called 911 and I remember getting in the ambulance thinking it was silly. I had a small seizure in the ambulance and when we got to the ER, I had a major grand-mal seizure. They did a quick cat-scan and saw a large mass in my head so they put me on a helicopter and flew me to a bigger hospital where they operated the next morning to remove the baseball size tumor in my brain. The pathology came back with the bad news -- grade 4 glioblasoma multiform (GBM) Prognosis, 6 months to live.

What types of cancer treatments were recommended?

I originally saw a general oncologist who had one clinical trial to offer but it was a randomized study, meaning a computer would pick if I got the treatment. I thought that was stupid. Then he gave me the best advice possible -- he told me to see a NEURO oncologist -- someone who specialized in heads.

Why are many early-stage pancreatic cancers not treated with life-extending surgery? It seems that one of the reasons might be that physicians in general have pessimistic views toward all patients diagnosed with pancreatic cancer and are subsequently not being offered surgery.

There are instances where surgery is not an option but it seems that many cases, more often patients over the age of 65, African Americans, patients with lower incomes or those who are on Medicare or Medicade are passed over and not given this life-extending surgery and a chance for cure.

A study published this week by the Annals of Surgery said there is an under-use of curative resection for pancreatic cancer. Pancreatectomy is the primary treatment for early-stage disease. Over the years the survival results from this surgery have improved, giving at this time 19 percent of patients a five-year survival rate.

Now here's some good news for Tamoxifen-taking, hot-flash suffering women. A new study finds women who have lots of hot flashes during treatment with the breast cancer drug Tamoxifen have a lower risk of recurrence than women who don't suffer from the annoying waves of heat commonly associated with menopause.

"This study provides the first evidence that hot flashes may be an indicator of a better prognosis in women with early stage breast cancer," said study author John P. Pierce, Ph.D., from the University of California at San Diego. "Our data supports the possibility of a significant association between hot flashes and disease outcome."

More study is necessary to determine whether or not hot flashes -- which may predict better outcomes than severity of cancer, hormone receptor status, and age -- are associated with Tamoxifen and breast cancer progression.

Award-winning jazz musician and former basketball star Wayman Tisdale revealed this week on his website that he has been diagnosed with cancer, that he will begin a six-month course of chemotherapy this week, and that his prognosis for recovery is excellent.

The 6-foot-9 former Oklahoma Sooners basketball great -- who played 12 seasons in the NBA with the Indiana Pacers, Sacramento Kings, and Phoenix Suns and helped score gold on the 1984 U.S. Olympic team -- reports that he broke his leg in a fall at his Los Angeles home last month.

After his fall, Tisdale's doctors determined a cyst in his right knee caused the injury. The cyst, identified as cancer, was then removed. Following chemotherapy, Tisdale, 42, will undergo knee-replacement surgery.

Tisdale has been told to hold off on his touring and public appearance schedules so can fully recover. But he plans to begin performing again in January 2008. In the meantime, he will focus on his new album with the working title Rebound.

This comment just arrived in response to yesterday's post Headed for melanoma, and it's just too raw and powerful to leave buried in the comment section of the site.

So here it is, word for word -- a chilling and empowering message from a 37-year-old mom of two living with a disease that is downright deadly.

I have melanoma. I was diagnosed last August and have had 6 surgeries in 6 months.

I have lost 4 members in my melanoma support group. I go to Jaime's funeral tomorrow afternoon. She was 29 years old. Heather was 37 when she died on March 2, 2007. The midwife noticed a suspicious mole on her leg during the birth of her 4th child. She died 23 months later. Jan was a mother of 5 ages 9 to 19, she passed away on February 8, 2007. Ceri was only 20 years old when melanoma claimed her life on January 14, 2007.

I always thought skin cancer had to be HUGE, ugly, and hard to ignore. I didn't know it could be small, have no symptoms, and KILL you.

Melanoma incidence is increasing faster than any other cancer. According to statistics found on the American Cancer Society's website (www.cancer.org), the prognosis for someone diagnosed with melanoma is worse, stage for stage, than someone with breast cancer.

Getting more than 3 blistering sunburns during childhood doubles your risk. Sunbed use increases ones risk. Having fair skin and light eyes also puts you at a higher than average risk, but having dark skin does not make you immune. Bob Marley died from Melanoma in 1981.

Everyone at higher risk should get screened by a dermatologist every year. And all of us should be checking our own skin each month.

Melanoma is a virulent and aggressive cancer. It begins in the melanocytes, or the pigment in the skin. It presents itself as a change in an existing mole or skin pigment, or in the formation of a new one. It is easily treated in its most early stages. Once it spreads, though, it is often fatal.

Unfortunately, there is no cure for melanoma. Melanoma is one of the cancers that won't respond to conventional chemotherapy. There have been no significant advances in the medical treatment or survival rate in the last 30 years.

More awareness is needed. Most think "it's only skin cancer" and consider it nothing serious. But I can tell you with absolute certainty, they are DEAD wrong.

Lung and colorectal cancer drug Avastin has been tested for the first time against the most common and deadly form of brain cancer.

Duke University researchers used Avastin, known chemically as bevacizumab, in combination with a standard chemotherapy agent in patients with recurrent brain tumors called gliomas. Good news -- the two drugs together stopped tumor growth for twice as long as any other therapy.

Gliomas are mostly incurable in all cases, but this new treatment approach may extend life and may help preserve physical and mental function for a longer period of time for patients fighting this deadly disease.

"These results are exciting because of the possible implications for a patient population that currently has the poorest possible prognosis going into treatment -- those with malignant brain tumors that have recurred after initial treatment," says the lead researcher whose findings appear in the journal Clinical Cancer Research.

Farrah Fawcett turned 60 on Friday. And she's been celebrating this milestone along with a very important message she just received -- she is cancer-free.

Fawcett, former star of the hit 1970s TV drama Charlie's Angels, was diagnosed with anal cancer four months ago and has been enduring an aggressive treatment protocol to treat the disease -- a treatment that appears to have worked.

Her physician, Dr. Gary Gitnick at the University of California, Los Angeles, medical school reports Fawcett "has had a full and complete response to treatment." Recent tests show her cancer is gone -- and Gitnick calls her prognosis excellent.

Fawcett calls the whole experience a hopeful one.

"In the face of excruciating pain and uncertainty, I never lost hope," she said. "I hope that my news might offer some level of inspiration to others who unfortunately must continue to fight the disease."

A new study shows that African Americans have the lowest colon cancer survival rate. The researchers think the racial gap may be due to a few different factors including colon cancer screening and treatments given.

The study included 14,000 adults diagnosed with colon cancer or rectal cancer. Eleven percent where African Americans, all had health insurance. They were the most likely to die of their disease, were more likely to be diagnosed with advanced tumors and less likely than whites to undergo colorectal cancer surgery.

Tumor stage and treatment seem to account for the racial gap in survival but the researchers think there might be other factors they are not aware of at this time.

Cancer of the unknown primary is when cancer is found somewhere in the body but the pathologist is unable to tell where the cells originated from. The cancer cells are so poorly differentiated that they do not resemble any cells of the body. It can be very difficult to find the right treatment because doctors usually use the type of cancer as the main starting point to choose chemotherapy or treatments that are known to be effective. Other problems arise with this type of diagnoses. Many physicians do not have much to go on to treat this disease or know if the patient is likely to survive.

French researchers have developed a prognostic model for cancer of the unknown primary. The findings were published in the December 1st issue of Cancer. Low serum albumin levels and elevated serum lactate dehydrogenase (LDH) in the blood of patients had the worse prognosis overall. This prognostic model can show who has the most powerful adverse prognostic factors.

Even with this information though, it doesn't seem to have anything to do with treatment. They can tell who has a better or worse prognosis but what then?

Previous posts on the topic:

Cancer of the unknown primary

Oncotype DX is a diagnostic test that quantifies the likelihood of disease recurrence in women with early stage, node negative breast cancer. With the information provided by the test it may be possible for doctors and patients to make more informed decisions about breast cancer treatment options.

Oncotype DX analyzes a specific set of genes within a tumor to determine a recurrence score. The recurrence score is a number between 0 and 100 that corresponds to the likelihood that a recurrence with happen within 10 years of initial diagnosis.

Results presented at the 2006 annual San Antonio Breast Cancer Symposium (SABCS) stated that the Oncotype DX test can more accurately predict estrogen receptor (ER) status than the two other commonly used tests, immunohistochemistry and ligand binding.

Another Oncotype DX study presented at the SABCS said that the test could predict the response to Tamoxifen by the levels of estrogen expression.

The researchers concluded that ER and PR expression, as measured using the Oncotype DX test, provide different pieces of information about prognosis and likely response to Tamoxifen among patients with node-negative breast cancer.

A not-so-new tumor-cell biomarker has been newly unveiled by researchers. And it just might predict how well women will fare after they've been diagnosed with breast cancer and how to best treat each cancer.

When expression of the marker -- called p27 -- is low, especially among women with hormone-receptor-positive tumors, prognosis is typically poor.

P27 was first discovered more than a decade ago but has not been useful for prognostic purposes until now. Previous studies on the marker failed to deliver all patients the same treatment -- so researchers could never determine if outcomes were due to p27 or treatment. But a recent study -- published in the December 6 issue of the Journal of the National Cancer Institute -- followed the same patients receiving the same treatment for newly diagnosed, hormone-receptor-positive, moderate-risk breast cancer.

The new study found women with tumors high in p27 expression had a five-year survival rate of 91 percent. Women with a low expression had a five-year survival rate of 85 percent.

No association was found between p27 expression and survival among women with hormone-receptor-negative tumors.

The next step in the study of this potentially important marker is to better define how women will benefit from this information.